Last Tuesday our CMO John Wagner, MD, PhD joined jp clancy, Andrew E. M., Robert Schuck and Nancy M. Allen LaPointe in a lively discussion around Integrating Sensitive Endpoints in Early-Phase Trials at Duke-Margolis Institute for Health Policy’s workshop around Opportunities to Improve Dose-Finding and Optimization for Rare Disease Drug Development. The discussion included best practices and considerations when selecting appropriate clinical outcome assessments that are also meaningful to patients, with a focus on strategies for integrating sensitive endpoints in early phase trials, including digital measurements. #drugdevelopment #digitalbiomarkers #biomarkers
Koneksa’s Post
More Relevant Posts
-
Unlock the Power of Personalized Medicine with PGx Testing FirmaLab Bio-Diagnostics 1️⃣ Optimized Treatments: PGx ensures medications are tailored to a patient’s genetic profile, minimizing trial-and-error prescribing. 2️⃣ Improved Patient Outcomes: Reduce adverse drug reactions and enhance treatment effectiveness, leading to better patient care. 3️⃣ Cost Efficiency: Avoid unnecessary prescriptions and hospitalizations with data-driven medication decisions. PGx: The future of precision medicine is here. Let’s help patients get the right drug at the right dose the first time. #Pharmacogenomics #PGxTesting #PersonalizedMedicine #PrecisionMedicine #HealthcareInnovation #PatientCare #Genomics #FutureOfHealthcare #DivineConceptsManagement
-
Care for lupus patients is evolving, with innovation accelerating in recent years. At AstraZeneca, we’re working closely with experts such as Dr Ian Bruce and Dr Julia Weinmann-Menke, who recently shared their insightful opinions on the following in an EMJ article: • Current state of SLE care • Recent updates to clinical recommendations elevating earlier intervention and steroid-tapering • Achieving remission as a key care goal Read this interesting piece here: https://bit.ly/4hl8yNM #MakeLupusVisible #TransformLupus
-
-
Care for lupus patients is evolving, with innovation accelerating in recent years. At AstraZeneca, we’re working closely with experts such as Dr Ian Bruce and Dr Julia Weinmann-Menke, who recently shared their insightful opinions on the following in an EMJ article: • Current state of SLE care • Recent updates to clinical recommendations elevating earlier intervention and steroid-tapering • Achieving remission as a key care goal Read this interesting piece here: https://bit.ly/4hl8yNM #MakeLupusVisible #TransformLupus
-
-
Care for lupus patients is evolving, with innovation accelerating in recent years. At AstraZeneca, we’re working closely with experts such as Dr Ian Bruce and Dr Julia Weinmann-Menke, who recently shared their insightful opinions on the following in an EMJ article: • Current state of SLE care • Recent updates to clinical recommendations elevating earlier intervention and steroid-tapering • Achieving remission as a key care goal Read this interesting piece here: https://bit.ly/4hl8yNM #MakeLupusVisible #TransformLupus
-
-
Executive Director and Head Of Statistical Programming, Respiratory and Immunology at AstraZeneca
Care for lupus patients is evolving, with innovation accelerating in recent years. At AstraZeneca, we’re working closely with experts such as Dr Ian Bruce and Dr Julia Weinmann-Menke, who recently shared their insightful opinions on the following in an EMJ article: • Current state of SLE care • Recent updates to clinical recommendations elevating earlier intervention and steroid-tapering • Achieving remission as a key care goal Read this interesting piece here: https://bit.ly/4hl8yNM #MakeLupusVisible #TransformLupus
-
-
Creative B2B marketing, communications and branding. Trend scout at the intersection of industry and design.
Making rare disease drug development happen, and happen faster, by looking at rare disease drug development paradigms, and how to shift them. All explained in Volv Global SA's talk at the World Orphan Drug Congress Europe 2024, next Wednesday - see you there!
You can't understand what's really important to the people in the healthcare ecosystem without talking to them directly. For a few years now, Volv Global SA has been consulting with key stakeholders on the challenges and what's needed to change the paradigms for rare disease drug development. At the World Orphan Drug Congress Europe 2024, our CEO 💭 Christopher Rudolf will present our findings to-date! "Drive for change: paradigm shifts to accelerate rare disease drug development" - Wednesday, 23rd October, 4.10 p.m., at Theater 5 (Precision Medicine track). Details in the comments! #driveforchange #paradigmshift #drugdevelopment #raredisease #orphandrug #volvglobal #christopherrudolf #wodc2024 #worldorphandrugcongress
-
Associate Principal Scientist Inhalation, TOSI, Global Operations, AstraZeneca, Macclesfield
Care for lupus patients is evolving, with innovation accelerating in recent years. At AstraZeneca, we’re working closely with experts such as Dr Ian Bruce and Dr Julia Weinmann-Menke, who recently shared their insightful opinions on the following in an EMJ article: • Current state of SLE care • Recent updates to clinical recommendations elevating earlier intervention and steroid-tapering • Achieving remission as a key care goal Read this interesting piece here: https://bit.ly/4hl8yNM #MakeLupusVisible #TransformLupus
-
-
Care for lupus patients is evolving, with innovation accelerating in recent years. At AstraZeneca, we’re working closely with experts such as Dr Ian Bruce and Dr Julia Weinmann-Menke, who recently shared their insightful opinions on the following in an EMJ article: • Current state of SLE care • Recent updates to clinical recommendations elevating earlier intervention and steroid-tapering • Achieving remission as a key care goal Read this interesting piece here: https://bit.ly/4hl8yNM #MakeLupusVisible #TransformLupus
-
-
Care for lupus patients is evolving, with innovation accelerating in recent years. At AstraZeneca, we’re working closely with experts such as Dr Ian Bruce and Dr Julia Weinmann-Menke, who recently shared their insightful opinions on the following in an EMJ article: • Current state of SLE care • Recent updates to clinical recommendations elevating earlier intervention and steroid-tapering • Achieving remission as a key care goal Read this interesting piece here: https://bit.ly/4hl8yNM #MakeLupusVisible #TransformLupus
-
